David R Raleigh
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Meningiomas are the most common primary brain tumors and, despite their benign reputation, often behave aggressively. Meningiomas are morphologically heterogeneous, yet the full significance of their histologic diversity is unclear. This is in large part because many features are not readily quantifiable by traditional observer-based light microscopy. Molecular testing improves prognostic stratification, but is not universally accessible. We therefore sought to determine whether an artificial intelligence (AI)-trained program could predict specific genomic and epigenomic patterns in meningiomas, and whether it could extract more prognostic information out of standard hematoxylin and eosin (H&E) histopathology than the current WHO classification. To do this, we developed Morphologic Set Enrichment (MSE), an interpretable computational pathology framework that quantifies statistical enrichment of morphologic patterns, cells, and tissue architecture from H&E whole-slide images. The MSE meningioma histology program was able to accurately predict DNA methylation subtypes and concurrent chromosome 1p/22q losses, in the process identifying specific morphologic patterns associated with key genomic and epigenomic alterations. It also added prognostic value independent of standard clinical and pathological variables. These results demonstrate that AI-based quantitative morphologic profiling can capture clinically and biologically relevant information that redefines risk stratification for meningiomas, incorporating histological information not included in existing grading schemes.
Year:
2026
Background Meningioma-induced hyperostosis (MIH) is a frequent radiographic finding, yet its underlying mechanisms remain poorly understoodWhile hyperostosis has traditionally been treated as a binary phenomenon, the aim of this study was to determine whether MIH represents a heterogenous process with distinct radiological subtypes associated with genetic associations. Methods We retrospectively reviewed the records and imaging of patients with meningiomas resected between 2021-2024 at a single institution. Somatic mutations identified through next-generation sequencing were analyzed. CT images were analyzed for bone involvement and hyperostosis subtype. Type I hyperostosis was defined by destruction of cortical architecture while Type II hyperostosis was defined by the preservation of cortical structure. Associations with TRAF7 mutations were assessed using univariate testing, multivariable logistic regression, and supervised machine-learning models. Quantitative bone density analysis was performed using region-of-interest grayscale histogram analysis. Results Among 384 tumors, 54 (14.1%) exhibited hyperostosis—23 Type I and 31 Type II. TRAF7 mutations were significantly enriched in Type I hyperostosis compared with Type II and non-hyperostotic tumors (78.3% vs 25.8% vs 17.0%, p<0.001). Type I hyperostosis independently predicted TRAF7 mutations (OR:18.73, p=0.001), along with skull base location, smaller tumor size, homogeneous contrast enhancement, and extensive T2 hyperintensity. Gradient boosting achieved the highest predictive accuracy (AUC=0.854). Quantitative bone density analysis demonstrated preserved cortical–cancellous architecture in Type II hyperostosis, whereas Type I showed architectural disruption. Conclusions MIH is a radiographically heterogenous phenomenon. Hyperostosis with disrupted cortical architecture is strongly associated with TRAF7 mutations and may represent a key feature of this mutation’s radiographic phenotype.
Year:
2026
The histone methyltransferase Polycomb repressive complex 2 (PRC2) is required for specification of the neural crest, and mis-regulation of neural crest development can cause severe congenital malformations. PRC2 is necessary for neural crest induction, but the embryonic, cellular, and molecular consequences of PRC2 activity after neural crest induction are incompletely understood. Here, we show that Eed , which encodes a protein that is a core subunit of PRC2, is required for craniofacial osteoblast differentiation and mesenchymal proliferation after induction of the neural crest. Integrating mouse genetics with single-cell RNA sequencing and epigenetic profiling, our results reveal that conditional knockout of Eed after neural crest cell induction causes severe craniofacial hypoplasia, impaired craniofacial osteogenesis, and attenuated craniofacial mesenchymal cell proliferation that is first evident in post-migratory neural crest cell populations. We show that Eed drives mesenchymal differentiation and proliferation in vivo and in primary craniofacial cell cultures by epigenetically regulating diverse transcription factor programs that are required for specification of post-migratory neural crest cells. These data enhance understanding of epigenetic mechanisms that underlie craniofacial development and shed light on the embryonic, cellular, and molecular drivers of rare congenital syndromes in humans.
Year:
2025
Group 3 (G3) medulloblastoma constitutes the most aggressive molecular subgroup, and nearly all patients present with metastases upon recurrence. Treatment for newly diagnosed medulloblastoma relies on a combination of maximal safe surgical resection, followed by chemotherapy and ionizing radiation, and no therapies have been shown to confer a survival benefit at the time of recurrence. Given the limited therapeutic options available for patients with medulloblastoma, especially at recurrence, and the incomplete understanding of the molecular mechanisms underlying resistance to treatment, we sought to uncover actionable targets and biomarkers that could help refine patient selection and treatment of newly diagnosed medulloblastoma to reduce the risk of recurrence. In clinically relevant mouse models of G3 medulloblastoma, CT-guided fractionated radiotherapy extended overall survival and induced the clonal selection of radioresistant subpopulations of tumor cells that drove medulloblastoma recurrence. Comparison of recurrent tumors with treatment-naïve newly diagnosed tumors revealed a gene expression signature that was found to be a biomarker of radioresistance and poor prognosis. This prognostic gene signature was shown to be subgroup specific in a large patient cohort. Recurrent tumors had elevated expression of carbonic anhydrase 4, and genetic and pharmacologic modulation of carbonic anhydrase 4 could promote or reduce resistance to radiotherapy. These data suggest that the FDA-approved carbonic anhydrase inhibitor acetazolamide may be a useful radiosensitizer to improve the efficacy of the treatment of newly diagnosed G3 medulloblastoma that could reduce the risk of tumor recurrence and improve survival in pediatric patients. Significance: G3 medulloblastoma features a prognostic subgroup-specific gene expression signature and can be targeted with a carbonic anhydrase inhibitor to enhance radiosensitivity, reducing the risk of recurrence and improving survival.
Year:
2025
Oligodendrogliomas are initially slow-growing brain tumors that are prone to malignant transformation despite surgery and cytotoxic therapy. Understanding of oligodendroglioma evolution and new treatments for patients have been encumbered by a paucity of patient-matched newly diagnosed and recurrent tumor samples for multiplatform analyses, and by a lack of preclinical models for interrogation of therapeutic vulnerabilities that drive oligodendroglioma growth. Here we integrate spatial and functional analyses of tumor samples and patient-derived organoid co-cultures to show that synaptic connectivity is a hallmark of oligodendroglioma evolution and recurrence. We find that patient-matched recurrent oligodendrogliomas are enriched in synaptic gene expression programs irrespective of previous therapy or histologic grade. Analyses of spatial, single-cell, and clinical data reveal epigenetic misactivation of synaptic genes that are concentrated in regions of cortical infiltration and can be used to predict eventual oligodendroglioma recurrence. To translate these findings to patients, we show that local field potentials from tumor-infiltrated cortex at the time of resection and neuronal hyperexcitability and synchrony in patient-derived organoid co-cultures are associated with oligodendroglioma proliferation and recurrence. In preclinical models, we find that neurophysiologic drugs block oligodendroglioma growth and pathologic electrophysiology. These results elucidate mechanisms underlying oligodendroglioma evolution from an indolent tumor to a fatal disease and shed light on new biomarkers and new treatments for patients.
Year:
2025
Supplementary Fig. 6. WHO grade 3 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 is expressed in and out of the perivascular niche, and colocalizes with mural cells in the perivascular niche, in meningiomas with WHO grade 3 histology. SF numbers indicate individual meningiomas. Representative of n=10 WHO grade 3 meningiomas. WHO grade defined using histological criteria. Scale bars, 10µm.
Year:
2024
Supplementary Table S1. Cell cluster marker genes from single-cell RNA sequencing of human meningiomas with loss of chromosome 22q. Supplementary Table S2. Cell cluster marker genes from single-cell RNA sequencing of dog meningiomas. Supplementary Table S3. RNA sequencing differential expression analyses across recurrent versus primary human meningiomas. Supplementary Table S4. Antibodies for multiplexed sequential immunofluorescence. Supplementary Table S5. Cell cluster marker genes from single-cell RNA sequencing of human cells from meningioma xenografts. Supplementary Table S6. Cell cluster marker genes from single-cell RNA sequencing of mouse cells from meningioma xenografts.
Year:
2024
Supplementary Fig. 5. WHO grade 2 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is primarily restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 2 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 2 meningiomas. Scale bars, 10µm.
Year:
2024
Supplementary Fig. 4. WHO grade 1 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 1 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 1 meningiomas. Scale bars, 10µm.
Year:
2024
Supplementary Fig. 13. Analysis of human and mouse cell types from single-cell RNA sequencing of meningioma xenografts. A, Feature plots showing differentially expressed genes across UMAP clusters from CH-157MN meningioma xenograft human cells analyzed using single-cell RNA sequencing. See also Supplementary Table 5. B, Meningioma xenograft human single-cell cluster changes across experimental conditions and biological replicates. Student’s t -tests. C, Single-cell RNA sequencing UMAP of 34,902 meningioma xenograft mouse cell transcriptomes showing microenvironment cell types. D, Feature plots showing differentially expressed genes across UMAP clusters from meningioma xenograft mouse cells analyzed using single-cell RNA sequencing. E, Meningioma xenograft mouse single-cell cluster changes across experimental conditions and biological replicates. See also Supplementary Table 6. Student’s t tests.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (40)
Jennie W Taylor
University of California
Aparna Bhaduri
Assistant Professor
University of California, Los Angeles
Brisa Palikuqi
Assistant Professor
Yale University
Craig Horbinski
Northwestern University
Nevan Krogan
Professor
University of California, San Francisco
Ana S. Guerreiro Stucklin
University of Zurich
Peter J. Dickinson
-
James Chandler
Vice-Chair
Northwestern University
Ophir Klein
Cedars-Sinai Medical Center
Paola Bisignano
Research Associate Professor
Vanderbilt University School of Medicine
Alan Ashworth
University of California, San Francisco
Shawn L. Hervey‐Jumper
Professor
University of California, San Francisco
Craig Daniels
Associate Professor
Baylor College of Medicine
Stephen T. Magill
Assistant Professor
Northwestern University
Ezequiel Goldschmidt
University of California
Amy B. Heimberger
Professor
Northwestern University
Calixto-Hope G Lucas
Johns Hopkins University School of Medicine
Christine M. Toedebusch
University of California
Vaibhav Jain
Duke University
Ichiyo Shibahara
Kitasato University
Danielle Swaney
University of California, San Francisco
Jüri Reimand
Associate professor
University of Toronto
Linda Liau
Professor
Ronald Reagan UCLA Medical Center
Arie Perry
University of California, San Francisco
Thomas Merchant
Chair
St. Jude Children's Research Hospital
Jared Ahrendsen
Assistant Professor
Northwestern University Feinberg School of Medicine
Benjamin Deneen
Associate Professor
Baylor College of Medicine
Kwanha Yu
Assistant Professor
Baylor College of Medicine
Michael Taylor
Professor
Baylor College of Medicine
Olivier Saulnier
Chaire de Professeur Junior
INSERM
Jeffrey O. Bush
University of California, San Francisco
Lee A D Cooper
Associate Professor, Director, Computational Pathology
Northwestern University
Nicholas Alexander Bayley
University of California, Los Angeles
Chittibabu Guda
Professor
University of Nebraska Medical Center
Felix Sahm
University Hospital Heidelberg
Joanna J. Phillips
Profesor
University of California, San Francisco
Richard Everson
Assistant Professor In Residence
David Geffen School of Medicine at UCLA
Olga Anczukow
Professor
Jackson Laboratory - Farmington
Simon G. Gregory
Professor
Duke University
Harish Vasudevan
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.